Vividion Publishes Discovery of First-in-Class KEAP1 Activator, Supporting Ongoing Clinical Program in Oncology [Yahoo! Finance]
BAYER AG S/ADR (BAYRY)
NASDAQ:AMEX Investor Relations:
investor.bayer.com
Company Research
Source: Yahoo! Finance
Preclinical data show antitumor activity and enhanced sensitivity to chemotherapies and radiotherapy across multiple NRF2-dependent cancer models Research provides foundational mechanistic insights underlying Vividion's Phase I KEAP1 activator, VVD-037 SAN DIEGO, December 22, 2025 BUSINESS WIRE Vividion Therapeutics , Inc. (Vividion), a clinical-stage biopharmaceutical company, and a wholly owned and independently operated subsidiary of Bayer AG, today announced the publication of a manuscript describing the discovery and preclinical characterization of small molecules that activate KEAP1 via a novel covalent allosteric molecular glue mechanism to drive degradation of NRF2. The article, " A covalent allosteric molecular glue suppresses NRF2-dependent cancer growth " (Roy et al., Cancer Discov. ), establishes NRF2 degradation via KEAP1 activation as a promising therapeutic approach for NRF2-activated cancers, including non-small cell lung cancer, esophageal squamous cell carcino
Show less
Read more
Impact Snapshot
Event Time:
BAYRY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BAYRY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BAYRY alerts
High impacting BAYER AG S/ADR news events
Weekly update
A roundup of the hottest topics
BAYRY
News
- Bio-Industry Leader Ashish Malik Named DunhamTrimmer Managing Partner & Chief Strategy Officer [Yahoo! Finance]Yahoo! Finance
- Pesticides Coalition: Canada Must Choose Science and Health Over Lobbyists [Yahoo! Finance]Yahoo! Finance
- Introducing Sivanto Energy: Enhanced Flea Beetle ControlBusiness Wire
- Pivot Bio Fortifies Commercial Leadership Team [Yahoo! Finance]Yahoo! Finance
- Bayer: Is This The Turning Point Investors Have Been Waiting For? [Seeking Alpha]Seeking Alpha